Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525333 | 1.00 | TYMP (0.47) | TYMPP2RY14P2RY2P2RY12P2RY6 | |
| SCHEMBL18034343 | 1.00 | TYMP (0.47) | TYMPP2RY14P2RY2P2RY12P2RY6 | |
| SCHEMBL12212802 | 0.96 | TYMP (0.44) | TYMPP2RY14P2RY2P2RY12P2RY6 | |
| SCHEMBL18034264 | 0.91 | TYMP (0.48) | TYMPP2RY14P2RY2P2RY12P2RY6 | |
| SCHEMBL13785236 | 0.90 | TYMP (0.47) | TYMPP2RY14P2RY2P2RY12P2RY6 | |
| SCHEMBL2526854 | 0.90 | TYMP (0.47) | TYMPP2RY14P2RY2P2RY12P2RY6 | |
| SCHEMBL2526851 | 0.90 | TYMP (0.47) | TYMPP2RY14P2RY2P2RY12P2RY6 | |
| SCHEMBL7553293 | 0.89 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL6831398 | 0.89 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 | |
| SCHEMBL4451613 | 0.89 | TYMP (0.51) | TYMPP2RY14P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006293-B1 | 2'-HYDROXYL-MODIFIED RIBONUCLEOSIDE DERIVATIVE | TOKYO INST TECH (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-8039611-B2 | 2′-hydroxyl group-modified ribonucleoside derivatives | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100016574-A1 | 2'-Hydroxyl Group-Modified Ribonucleoside Derivatives | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2006293-A9 | 2'-HYDROXYL-MODIFIED RIBONUCLEOSIDE DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-2006293-A2 | 2'-HYDROXYL-MODIFIED RIBONUCLEOSIDE DERIVATIVE | Tokyo Institute of Technology (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016574-A1 | 2'-Hydroxyl Group-Modified Ribonucleoside Derivatives | RNASEH1, RNASEL, NSUN2 | TYMP 878/4885P2RY14 4837/4885P2RY2 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.